Get the app
US › Healthcare

Biocardia Inc (BCDA)

US · Healthcare · Biotechnology

$0.85-4.49%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Net profit
$-1.6M
EPS
$-0.13
EPS estimate
$-0.19

EPS came in at -0.13 against a street estimate of -0.19 — a beat of 31.6%.

Key statistics

Market cap
$13.5M
Forward P/E
0.0
P/B
5.20
Book value
$0.18
EPS (TTM)
$-0.64
52-week high
$1.50
52-week low
$0.75
50-day MA
$1.03
200-day MA
$1.07
Beta
0.65

Analyst view

Analysts rate Biocardia Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $15.50.

Shareholding

Insiders
17.93%
Institutions
14.80%

Largest institutional holders

FundStake
Citigroup Inc2.63%
CM Management, LLC1.98%
Vanguard Capital Management, LLC0.82%
Pingora Partners LLC0.80%
UBS Group AG0.51%
Geode Capital Management, LLC0.44%
Vanguard Fiduciary Trust Co0.44%
Susquehanna International Group, LLP0.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biocardia Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.